Mendus - ADVANCE II survival data confirms positive MRD results
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Redeye via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
2022-12-15 07:39:00
Redeye comments on Mendus presenting ADVANCE II survival data at ASH 2022. The study had not yet reached median relapse-free survival after a median c19.4 months follow-up, indicating considerably better mRFS than historical QUAZAR AML-001 controls. We increase our estimated likelihood of approval for DCP-001 and valuation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.